Oncology News & Perspectives

Featured Exclusive

Men with metastatic castration-sensitive prostate cancer (CSPC) generally experience an initial response to androgen deprivation therapy (ADT), but with time, the cancer invariably becomes castration resistant. A new analysis of data from the phase 3 CHAARTED trial, published last week in JAMA Oncology, shows that men with low-volume metastatic CSPC who have the adrenal-per...

Top Oncology Stories

Friday, February 21, 2020
In patients with previously treated advanced non-small cell lung cancer (NSCLC), anlotinib increases progression-free survival in squamous cell carcinoma (SCC) and improves ...
Thursday, February 20, 2020
Men with metastatic castration-sensitive prostate cancer (CSPC) generally experience an initial response to androgen deprivation therapy (ADT), but with time, the cancer invari...
Wednesday, February 19, 2020
In patients with previously treated advanced renal cell carcinoma (RCC), nivolumab significantly increases overall survival and response rates compared with everolimus, acco...
Tuesday, February 18, 2020
In the phase 3 REFLECT trial, lenvatinib, an oral multikinase inhibitor, showed non-inferior survival compared with sorafenib in patients with untreated, unresectable hepato...
Monday, February 17, 2020
​Intravesical nadofaragene firadenovec is an effective and well-tolerated treatment for high-grade nonmuscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) that does n...

Expert Perspectives

Men with metastatic castration-sensitive prostate cancer (CSPC) generally experience an initial response to androgen deprivation therapy (ADT), but with time, the cancer invariably becomes castration resistant. A new analysis ...
In the phase 3 REFLECT trial, lenvatinib, an oral multikinase inhibitor, showed non-inferior survival compared with sorafenib in patients with untreated, unresectable hepatocellular carcinoma (HCC). However, the assessment ...
​Because gastrointestinal stromal tumor (GIST) has an estimated incidence of 3,300 to 6,000 new cases per year in the United States, comprising less than 1% of all gastrointestinal tumors, the rarity of this tumor type can mak...
​With our ever-growing understanding of mutations that increase cancer risk and the rise of targeted treatments such as poly (ADP-ribose) polymerase (PARP) inhibitors that are indicated for specific mutations, the use of germl...
In the past decade, much progress has been made in the management of castration-resistant prostate cancer (CRPC), with numerous new agents improving outcomes in patients with this disease. However, many challenges still rem...

Original Research

At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats i...
Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has reveale...
Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment...
Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely rec...
As the number of treatments for recurrent ovarian cancer expands, confusion may develop over which therapeutic strategy is best to use. Numerous patient factors need to be taken into account when deciding on a treatment plan, such...

Copyright © 2020 i3 Health. All rights reserved.